Aclaris Therapeutics
ACRS
98 hedge funds and large institutions have $58.1M invested in Aclaris Therapeutics in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 38 reducing their positions, and 24 closing their positions.
1,175% more call options, than puts
Call options by funds: $51K | Put options by funds: $4K
0% more funds holding
Funds holding: 98 → 98 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
2.59% less ownership
Funds ownership: 76.77% → 74.17% (-2.6%)
14% less capital invested
Capital invested by funds: $67.8M → $58.1M (-$9.7M)
47% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$4.22M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.26M |
| 3 |
TC
Trium Capital
London,
United Kingdom
|
+$2.22M |
| 4 |
AC
Aldebaran Capital
Carmel,
Indiana
|
+$1.01M |
| 5 |
Goldman Sachs
New York
|
+$906K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.73M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$2.35M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.34M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$929K |
| 5 |
Renaissance Technologies
New York
|
-$883K |
ACRS Hedge Fund Activity: Q2 2024 in Review
98 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2024, worth a combined $58.1M — down 14% from $67.8M a quarter earlier.
Fund positioning in ACRS was balanced in Q2 2024: 24 funds opened new positions, 24 closed out, 20 added to existing stakes and 38 trimmed.
The largest buyer was BML Capital Management, adding an estimated $4.22M. The largest seller was BlackRock, cutting an estimated $3.73M.
- 98 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $58.1M of Aclaris Therapeutics stock for Q2 2024, down 14% quarter-over-quarter.
- 24 funds opened new Aclaris Therapeutics positions in Q2 2024 and 24 closed out, a net change of 0 holders.
- The largest Aclaris Therapeutics buyer in Q2 2024 was BML Capital Management, an estimated $4.22M added.
- The largest Aclaris Therapeutics seller in Q2 2024 was BlackRock, an estimated $3.73M sold.
Based on aggregated 13F filings for Q2 2024.